Brian Peter Zambrowicz
Direttore/Membro del Consiglio presso Texas A&M Institute for Genomic Medicine
Profilo
Brian Peter Zambrowicz is the founder of Lexicon Pharmaceuticals, Inc. which was founded in 1995.
He held the title of Chief Scientific Officer & Executive VP from 2011 to 2015.
Currently, he is the Director at Texas A&M Institute for Genomic Medicine.
He previously worked as a Director & Senior Scientific Advisor at Nuevolution AB.
Dr. Zambrowicz earned a doctorate degree from the University of Washington and an undergraduate degree from the University of Wisconsin.
Posizioni attive di Brian Peter Zambrowicz
| Società | Posizione | Inizio |
|---|---|---|
Texas A&M Institute for Genomic Medicine
 Texas A&M Institute for Genomic Medicine Miscellaneous Commercial ServicesCommercial Services Texas A&M Institute for Genomic Medicine focuses in research and development for medical industry. It was founded in 2006 and is headquartered in College Station, Texas. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Brian Peter Zambrowicz
| Società | Posizione | Fine |
|---|---|---|
| LEXICON PHARMACEUTICALS, INC. | Fondatore | 24/02/2015 |
| NUEVOLUTION AB (PUBL) | Direttore/Membro del Consiglio | - |
Formazione di Brian Peter Zambrowicz
| University of Washington | Doctorate Degree |
| University of Wisconsin | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| LEXICON PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Nuevolution AB
 Nuevolution AB Pharmaceuticals: MajorHealth Technology Nuevolution AB engages in pharmaceutical and biotechnology discovery. Its activities include research and development, and licensing drugs and treatment of oncology and chronic inflammatory diseases including cancer. It offers the platform Chemetics, which enables discovery of small molecule drug candidates for specific indications addressing target diseases. The company was founded by Henrik Pedersen, Alex Haahr Gouliaev, and Mads Nørregaard-Madsen in May 2001 and is headquartered in Copenhagen, Denmark. | Health Technology |
Texas A&M Institute for Genomic Medicine
Texas A&M Institute for Genomic Medicine Miscellaneous Commercial ServicesCommercial Services Texas A&M Institute for Genomic Medicine focuses in research and development for medical industry. It was founded in 2006 and is headquartered in College Station, Texas. | Commercial Services |
- Borsa valori
- Insiders
- Brian Peter Zambrowicz
